REGULATORY
Council Conditionally Approves 1st Technology for Use Under Patient-Initiated Mixed Care at Univ. of Tokyo Hospital
A health ministry’s council decided to recommend conditional approval of the intraperitoneal and intravenous administration of paclitaxel in combination with oral S-1 for the treatment of stomach cancer patients with peritoneal dissemination or positive peritoneal cytological diagnosis under “patient-initiated mixed…
To read the full story
REGULATORY
- Japan Targets Global-Level Growth for Domestic Patented Drug Market
June 25, 2026
- Paxlovid, Awiqli Braced for NHI Price Cuts after CEAs
June 25, 2026
- Drug Pricing to Be Applied to Oncolys Oncolytic Virus Therapy
June 25, 2026
- Japan Diet Begins Deliberations on Immunization Act Revision
June 25, 2026
- Expert Calls for AMR Ecosystem to Boost Japan Antibiotic Innovation
June 25, 2026
Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…





